PEDIATRICS Vol. 118 No. 2 August 2006, pp. 746-752 (doi:10.1542/10.1542/peds.2005-2664)
REVIEW ARTICLE |
Metoclopramide for the Treatment of Gastroesophageal Reflux Disease in Infants: A Systematic Review
Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
OBJECTIVES. Metoclopramide is a commonly used drug to treat gastroesophageal reflux disease in infants. Given its widespread use and growing concern about toxicity in this population, we conducted a systematic review of metoclopramide for the treatment of gastroesophageal reflux disease in infants.
METHODS. We performed a systematic search of PubMed and bibliographies of relevant review articles. We included cohort, case-control, and intervention studies of the efficacy, effectiveness, or toxicity of metoclopramide therapy for gastroesophageal reflux disease in infants. We excluded case reports, case series, review articles, and abstracts.
RESULTS. Twelve articles met our inclusion criteria. Of these, 11 were prospective trials, and 5 were randomized, blinded clinical trials. Study size ranged from 6 to 77 patients. Eight studies showed patient improvement with metoclopramide in at least 1 measured outcome; 1 study showed worsening symptoms with metoclopramide. Of the 5 randomized, blinded trials, 2 showed no effect of metoclopramide on any outcome, and 2 showed a significant placebo effect. Four studies commented on adverse effects of therapy, with irritability being the most frequently reported potential adverse effect of therapy. Other reported adverse effects included dystonic reactions, drowsiness, oculogyric crisis, emesis, and apnea. Among studies, there was marked heterogeneity in the patient populations, dosing, and outcomes studied. Therefore, a meta-analysis was not performed. We both agreed on a US Preventive Service Task Force rating of "poor" for the level of evidence, leading to an "inconclusive" recommendation for the safety and efficacy of metoclopramide in infants.
CONCLUSIONS. The current literature is insufficient to either support or oppose the use of metoclopramide for gastroesophageal reflux disease in infants. In the future, large blinded randomized clinical trials are needed to determine the efficacy and toxicity of metoclopramide in this population.
Key Words: systematic reviews metoclopramide infant gastroesophageal reflux
Abbreviations: GERgastroesophageal reflux GERDgastroesophageal reflux disease RCTrandomized, controlled trial USPSTFUS Preventive Services Task Force
Accepted Mar 8, 2006.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
R. C. Cook and T. A. Blinman The Case of the Wretched Retcher ICAN: Infant, Child, & Adolescent Nutrition, April 1, 2009; 1(2): 94 - 97. [Abstract] [PDF] |
||||
![]() |
F. Savino and E. Castagno Overprescription of Antireflux Medications for Infants With Regurgitation Pediatrics, May 1, 2008; 121(5): 1070 - 1070. [Full Text] [PDF] |
||||
![]() |
W. F. Malcolm, M. Gantz, R. J. Martin, R. F. Goldstein, R. N. Goldberg, C. M. Cotten, and for the National Institute of Child Health and Hum Use of Medications for Gastroesophageal Reflux at Discharge Among Extremely Low Birth Weight Infants Pediatrics, January 1, 2008; 121(1): 22 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Parashar, A. Varma, and B. Sharp Risperidone as Galactagogue? J Hum Lact, May 1, 2007; 23(2): 143 - 143. [PDF] |
||||
![]() |
R. J. Martin and A. M. Hibbs Diagnosing Gastroesophageal Reflux in Preterm Infants Pediatrics, August 1, 2006; 118(2): 793 - 794. [Full Text] [PDF] |
||||







